Diagnosis, clinical implications, and complications of onychomycosis.
Onychomycosis is defined as a fungal infection of the nail unit (Figure 1): the nail plate, nail bed, and periungual tissue. The most common culprits in immunocompetent patients are Trichophyton rubrum (90% of cases) and Trichophyton mentagrophytes (most of the remaining 10% of cases). (1) Less commonly, yeasts and nondermatophyte molds may be causative organisms, particularly in certain patient populations, such as patients with diabetes, the elderly, and immunocompromised individuals. (For further discussion in this supplement, see Scher et al. (2)) Onychomycosis caused by dermatophytes is significantly more common in toenails than in fingernails; the opposite is true of Candida infections, which are significantly more common in fingernails than in toenails. (3)
The physical examination should include careful inspection of all fingernails and toenails. The extent of involvement (the number of nails and the percentage of involvement of each nail unit) should be noted.
The clinical features of onychomycosis (Table 1) include nail bed hyperkeratosis with subsequent separation of the nail plate from the nail bed (onycholysis), the presence of subungual debris, and nail plate dyschromia. Individuals with onychomycosis also may experience associated inflammation and tenderness of the nail bed or periungual tissue. Concomitant tinea pedis infection (also caused by T. rubrum) is extremely common in patients with toenail onychomycosis.
Clinical Presentations: Patterns of Nail Plate Invasion
Several patterns of nail plate invasion have been described. (4) The most common of these is invasion of the nail plate from the hyponychium (distal-lateral-subungual owchomycosis) (Figure 2). In the presentation known as proximal subungual owchomycosis (Figure 3), the organisms invade the proximal nail bed via the cuticle. This is an unusual presentation in immunocompetent individuals; the presence of proximal subungual onychomycosis should raise the index of suspicion for an underlying cause of immunosuppression. Superficial white onychomycosis is characterized by direct invasion of the nail plate surface, causing leuconychia and crumbling of the plate (Figure 4).
Chronic mucocutaneous candidiasis is a presentation that is caused by Candida albicans, which affects the entire nail unit. Normally, Candida cannot invade the nail plate in immunocompetent patients. Candida may be a secondary invader in onycholysis and chronic paronychia (Figure 5).
Onychomycosis can mimic many other clinical conditions that affect the nail, such as trauma, other infections, and inflammatory processes including psoriasis and, occasionally, neoplastic conditions. When a solitary nail is involved, the possibility of a subungual tumor such as onychomatricoma or exostosis may be considered. The differential diagnosis of onychomycosis in adults is listed in Table 2. (5,6)
Exogenous substances can cause nail dyschromia that can mimic onychomycosis. Nail polish can stain the nail yellow, and other products, such as self-tanning cream, can stain the nail plate brown. Exposure to a number of substances can cause changes in nails that resemble infectious processes. In addition, physiologic changes occur with aging that resemble fungal dyschromia and dystrophy (Figure 6).
Finally, certain systemic medications are known to induce nail changes. For example, antineoplastic drugs may cause onycholysis, and sun exposure during tetracycline therapy may cause photo-onycholysis. Retinoids may cause nail brittleness.
In children, the differential diagnosis includes several uncommon clinical conditions (Table 3). (7) However, a history of owchomycosis and/or tinea pedis in the family or other household members suggests a dermatophyte infection.
Laboratory Confirmation of Clinical Diagnosis
The diagnosis of onychomycosis should be confirmed prior to institution of treatment. A diagnosis of onychomycosis often has been made based on clinical impressions alone, particularly in cases of mild infections limited to partial involvement of one or only a few nails and especially when topical therapy--rather than systemic therapy--is prescribed. However, this is no longer considered the ideal practice, given what is now known about the potential clinical sequelae of onychomycosis, the importance of selecting the most appropriate treatment, and the possibility of misdiagnosis of nail disease from other causes (such as immune dysfunction (8) or psoriasis (9)).
A definitive diagnosis of the presence of a fungal infection may be readily made in the office by use of a potassium hydroxide (KOH) preparation. In patients with the distal subungual pattern, the nail should be debrided as far back as possible and a specimen of subungual debris obtained from the area as close to the cuticle as possible (Figure 7). Alternatively, scale from the involved portion of the nail plate can be used. Scrapings from the surface of the involved nail plate is preferred in patients with suspected superficial white onychomycosis. In those with a proximal subungual presentation, it is necessary to sample the deeper nail plate and bed. To dissolve the subungual debris and make it easier to visualize the fungus, dimethyl sulfoxide can be added to the 10% to 15% KOH solution on the glass slide. Fungal stains (chlorazol black E or Parker blue-black ink) may be used to enhance microscopic visualization.
The main advantage of office-based testing is rapid confirmation that a fungus is present. The main disadvantage is that the fungus itself is not specifically identified nor is the presence of nondermatophyte organisms. Another disadvantage of direct microscopy is that an inexperienced observer may misinterpret the results.
KOH of subungual debris and periodic-acid Schiff (PAS) staining of nail plate samples provide confirmation of organisms but do not identify or ascertain the viability of organisms present. Culture is slower and less sensitive but currently is the standard method for identifying the causative organism. Polymerase chain reaction may become a useful method.
PAS showing septate hyphae is diagnostic, but PAS showing only yeast forms is not conclusive evidence of infection. Laboratory results of PAS staining of nail clippings are usually available within a few days. Nail clippings also may be obtained for histologic analysis.
The gold standard of diagnosis for onychomycosis is a fungal culture. Culturing is the only method that is widely available at this time that provides definitive identification of a specific organism, which is particularly important when yeasts or other nondermatophyte organisms are a suspected cause of onychomycosis. Such identification allows choice of a systemic agent that is most likely to be effective.
When other tests fail to provide definitive results, a nail biopsy should be considered. (10)
In most patients, it is likely that a clinical suspicion of dermatophytic onychomycosis can be derived based on the patient's personal and family history and on careful inspection of both fingernails and toenails. However, the diagnosis should be confirmed--using, at minimum, an office-based KOH preparation--prior to initiating therapy. In addition, under the circumstances described in this article, a culture should be performed to obtain a definitive diagnosis and identification of the causative organism.
Caption: Figure 1. Nail Anatomy The nail plate (consisting of keratin) forms in the matrix and is attached to the nail bed as it grows. Although the distal portion of the matrix is typically visible (as the lunula) in the thumb and forefinger, it is concealed under the proximal nail fold in the rest of the fingers and the toes. The proximal nail fold covers and adheres to the base of the nail; the distal portion of the proximal fold is the cuticle. Lateral nail folds form soft tissue boundaries at the sides of the nails.
Caption: Figure 2. Distal-lateral-subungual onychomycosis. Note the onycholysis, along with thickening, crumbling, and discoloration of the nail plate and subungual debris. Photo courtesy of Phoebe Rich, MD.
Caption: Figure 3. Proximal subungual onychomycosis. Proximal subungual onychomycosis. This presentation is marked by invasion of the proximal nail bed via the cuticle. It is unusual in immunocompetent patients. Photo courtesy of Antonella Tosti, MD, Professor of Dermatology, Department of Dermatology and Cutaneous Surgery, University of Miami, Leonard M Miller School of Medicine.
Caption: Figure 4. Superficial white onychomycosis. Leuconychia and crumbling, as seen in this patient, is a result of direct invasion of the nail plate surface. Photo courtesy of Phoebe Rich, MD.
Caption: Figure 5. Candidal onychomycosis.Onycholysis and chronic paronychia may result from invasion of Candida. In immunocompetent patients, this is secondary to other causes such as trauma or chronic exposure to water. Photo courtesy of Phoebe Rich, MD.
Caption: Figure 6. Dyschromia. Yellowing and discoloration may result from both onychomycosis and aging. Even after the infection has been successfully treated, age-related dyschromia can be expected to persist. Photo courtesy of Phoebe Rich, MD.
Caption: Figure 7. Sampling scrapings for KOH preparation or culture. A scraping of the surface of the nail (A) usually does not provide sufficient material for study. The most viable hyphae are under the nail plate; clipping followed by paring (B) yields the most useful sample. Photo courtesy of Phoebe Rich, MD.
(1.) Ghannoum MD, Hajjeh RA, Scher R, et al A large-scale North American study of fungal isolates from nails: The frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000;43:641-648.
(2.) Scher RK, Elewski B, Rich P, Pariser D. The epidemiology, etiology, and pathophysiology of onychomycosis. Semin Cutan Med Surg 2013;33:7-9.
(3.) Foster KW, Ghannoum MA, Elewski BE. Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002 J Am Acad Dermatol. 2004;50:748-752.
(4.) Baran R, Hay RJ, Tosti A, Haneke E. A new classification of onychomycosis. Br J Dermatol. 1998;139:567-571.
(5.) Cockerell C, Odom R. The differential diagnosis of nail disease. AIDS Patient Care. 1995;9(suppl 1):S5-S10.
(6.) Daniel CR III. The diagnosis of nail fungal infection Arch Dermatol. 1991: 127:1566-1567.
(7.) Tosti A, Piraccini BM, Iorizzo M. Management of onychomycosis in children. Dermatol Clin. 2003;21:507-509.
(8.) Sherber N, Wigley FM, Scher RK Autoimmune disorders: Nail signs and therapeutic approaches. Dermatol Ther. 2007;20:17-30.
(9.) Rich P, Griffiths CEM, Reich K. et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with in fliximab during 1 year. J Am Acad Dermatol. 2008;58:224-231.
(10.) Rich P. Nail biopsy: Indications and methods. Dermatol Surg. 2001;27:229-234.
Phoebe Rich, MD, * Boni Elewski, MD, ([dagger]) Richard K. Scher, MD, ([double dagger]), David Pariser, MD ([section])
* Clinical Adjunct Professor of Dermatology, Oregon Health Science University, Portland, OR
([dagger]) Vice-Chair for Clinical Affairs, Professor of Dermatology University of Alabama School of Medicine, Birmingham, AL
([double dagger]) Clinical Professor of Dermatology, Weill Cornell Medical College New York, NY
([section]) Professor of Dermatology, Eastern Virginia Medical School Department of Dermatology, Pariser Dermatology, Norfolk, VA
Publication of this CME article was jointly sponsored by the University of Louisville School of Medicine Continuing Medical Education and Global Academy for Medical Education, LLC and is supported by an educational grant from Medicis, a division of Valeant Pharmaceuticals.
The faculty have received an honorarium from Global Academy for Medical Education for their participation in this activity. They acknowledge the editorial assistance of Joanne Still, medical writer, and Global Academy for Medical Education in the development of this continuing medical education journal article. Joanne Still has no relevant financial relationships with any commercial interests.
Boni Elewski, MD, has been an investigator for Anacor and Valeant.
David Pariser, MD, has been a consultant and/or investigator and/or advisory board member with Abbott Laboratories, Amgen, Astellas Pharma US, Inc, Basilea, Celgene Corporation, Dow Pharmaceutical Sciences, Inc., DUSA Pharmaceuticals, Inc., Eli Lily and Company, Galderma Laboratories, L.P., Genentech, Inc., Graceway Pharmaceuticals, LLC, Intendis, Inc., Janssen-Ortho Inc, Johnson & Johnson Consumer Products Company, LEO Pharma, US, Medicis Pharmaceutical Corporation, MelaSciences, Novartis Pharmaceutical Corporation, Novo Nordisk A/S, Ortho Dermatologics, Peplin Inc., Pfizer, Photocure ASA, Proctor & Gamble Company, Stiefel a GSK company, and Valeant Pharmaceuticals International.
Phoebe Rich, MD, has been a principal investigator and/or consultant for Valeant, Dow Pharmaceuticals, Topica, and Tolmar.
Richard K. Scher, MD, is an advisor/consultant to Valeant.
Address reprint requests to: Phoebe Rich, MD, 2565 NW Lovejoy Street, Suite 200, Portland, OR 97210, Telephone: (503) 226-3376, E-mail: email@example.com
Table 1. Clinical Signs of Onychomycosis (Toenails or Fingernails) * Onycholysis * Debris under the nail plate * Subungual hyperkeratosis * Discoloration (usually nontransparent white or yellow discoloration; less frequently, brown pigmentation) * Destruction of all or part of the nail plate Table 2. Differential Diagnosis of Onychomycosis in Adults (5,6) * Psoriasis * Nail trauma * Contact irritants * Lichen planus * Neoplasms * Bacterial infection (Pseudomonas aeruginosa, Proteus mirabilis) Table 3. Differential Diagnosis of Onychomycosis in Children (7) * Nail psoriasis * Congenital malalignment of large toenail * Subungual exostosis * Subungual warts * Subungual hematoma * Paronychia secondary to finger sucking * Parakeratosis pustolosa
Please note: Illustration(s) are not available due to copyright restrictions.
|Printer friendly Cite/link Email Feedback|
|Author:||Rich, Phoebe; Elewski, Boni; Scher, Richard K.; Pariser, David|
|Publication:||Family Practice News|
|Date:||Sep 1, 2013|
|Previous Article:||The epidemiology, etiology, and pathophysiology of onychomycosis.|
|Next Article:||Current and emerging options in the treatment of onychomycosis.|